Henoch schonlein purpura--a 5-year review and proposed pathway

Louise Watson1, Amanda R W Richardson, Richard C L Holt

  • 1Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, United Kingdom. Louise.watson@liv.ac.uk

Plos One
|January 12, 2012
PubMed

Insights

We developed a new nurse-led pathway to monitor Henoch Schonlein Purpura (HSP) in children. This pathway identifies children at high risk for kidney problems, improving early detection and management of HSP nephritis.

Area of Science:

  • Pediatric Nephrology
  • Rheumatology
  • Clinical Pathway Development

Background:

  • Henoch Schonlein Purpura (HSP) is the most common childhood vasculitis, often affecting the kidneys.
  • Current monitoring pathways for HSP nephritis require critical assessment and revision.
  • Standardized monitoring is crucial for understanding disease course and facilitating research.

Purpose of the Study:

  • To clinically assess and revise a nurse-led monitoring pathway for Henoch Schonlein Purpura (HSP) in children.
  • To determine the incidence and natural disease course of HSP nephritis.
  • To develop an evidence-based pathway for screening poor renal outcomes in HSP.

Main Methods:

  • A cohort of 102 children with HSP was monitored over five years using a nurse-led pathway.
  • Incidence, disease course, and risk factors for renal involvement were analyzed.
  • A revised pathway, The Alder Hey Henoch Schonlein Purpura Pathway, was developed based on data and literature.

Main Results:

  • HSP incidence was 6.21 cases per 100,000 children/year.
  • 46% had initial renal inflammation, 9% required renal referral, and 1% needed biopsy/immunosuppression.
  • Older age and abnormal Day 7 urinalysis were associated with higher risk of renal referral; normal Day 7 urinalysis had 97% negative predictive value for normal renal outcome.

Conclusions:

  • The revised Alder Hey Henoch Schonlein Purpura Pathway prioritizes monitoring based on Day 7 urine findings, focusing on high-risk patients.
  • This standardized pathway can be adapted for various settings to improve HSP nephritis screening.
  • Implementing standardized pathways will aid disease registries and future clinical trials for HSP.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...